89.76
1.39%
1.13
Handel nachbörslich:
89.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$88.63
Offen:
$89.065
24-Stunden-Volumen:
2.88M
Relative Volume:
0.47
Marktkapitalisierung:
$110.72B
Einnahmen:
$28.30B
Nettoeinkommen (Verlust:
$126.00M
KGV:
20.63
EPS:
4.35
Netto-Cashflow:
$9.43B
1W Leistung:
-2.44%
1M Leistung:
+4.14%
6M Leistung:
+33.55%
1J Leistung:
+20.32%
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
GILD | 89.75 | 110.72B | 28.30B | 126.00M | 9.43B | 4.35 |
LLY | 749.56 | 703.88B | 40.86B | 8.37B | -2.28B | 5.4193 |
NVO | 102.65 | 467.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
JNJ | 155.49 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
ABBV | 171.71 | 296.46B | 55.53B | 5.12B | 15.62B | 3.65 |
MRK | 99.85 | 248.23B | 63.17B | 12.15B | 14.84B | 1.80 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
2023-07-24 | Bestätigt | Barclays | Equal Weight |
2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
2022-10-28 | Bestätigt | Cowen | Outperform |
2022-10-28 | Bestätigt | JP Morgan | Overweight |
2022-10-28 | Bestätigt | Jefferies | Buy |
2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
2022-10-28 | Hochstufung | Truist | Hold → Buy |
2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
2022-02-02 | Bestätigt | BofA Securities | Neutral |
2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
2022-02-02 | Bestätigt | Truist | Hold |
2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Argus | Hold → Buy |
2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-12-06 | Eingeleitet | Goldman | Neutral |
2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-09-30 | Fortgesetzt | Jefferies | Buy |
2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
2020-07-31 | Bestätigt | Credit Suisse | Neutral |
2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
2020-07-31 | Bestätigt | Piper Sandler | Overweight |
2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
2020-07-31 | Bestätigt | SunTrust | Hold |
2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
2020-04-27 | Herabstufung | UBS | Buy → Neutral |
2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00 - MarketBeat
Gilead’s GS-6791 ameliorates arthritis symptoms in mice - BioWorld Online
Intech Investment Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
PNC Financial Services Group Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Natixis Advisors LLC - MarketBeat
Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Legal Desire News Network
Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus.com
Gilead Sciences Issues $3.5 Billion in Senior Notes - Investing.com India
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer - CSRwire.com
How Gilead Is Driving Global Health Equity And Innovation - Forbes
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by First Horizon Advisors Inc. - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Ontario Teachers Pension Plan Board - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Takes $9.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Prospera Financial Services Inc Has $6.59 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead discloses GS-441524 prodrugs for treatment of viral infections - BioWorld Online
Ideaya hires Gilead leader to head up commercialization push - FiercePharma
Parnassus Investments LLC Sells 280,937 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Meeder Asset Management Inc. Purchases 42,444 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Belmont Capital LLC Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead announces impending layoffs, facility closure - LabPulse
26 Analysts Assess Gilead Sciences: What You Need To Know - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ - FiercePharma
Gilead’s Livdelzi shows promise in PBC clinical trial - Yahoo Finance
Gilead Sciences shares target upgraded, holds rating on HIV event outlook - Investing.com India
5,715 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Aljian Capital Management LLC - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TrinityPoint Wealth LLC - MarketBeat
Gilead Science to Report Q3 Earnings: What's in the Cards? - MSN
Empowering women, eliminating viral hepatitis: Gilead’s vision to help drive public health solutions - STAT
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - BioSpace
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewswire Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Swiss National Bank - MarketBeat
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
14,342 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Atlanta Consulting Group Advisors LLC - MarketBeat
How Gilead Sciences' HIV & Other Innovations Are Set to Capture Untapped Markets & Drive Massive Growth!Major Drivers - Smartkarma
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Kentucky Retirement Systems - MarketBeat
CIBC Asset Management Inc Purchases 22,624 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Impax Asset Management Group plc Sells 7,979 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead’s Irish business sees profit slump on falling sales of Covid drug - The Irish Times
Gilead to see Bay Area layoffs in wake of Seattle office closingSan Francisco Business Times - The Business Journals
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Form 424B5 GILEAD SCIENCES, INC. - StreetInsider.com
Biotech giant Gilead lays off 104 from Bay Area headquarters, including execs - SFGATE
Cell Therapy Market Poised for Massive Growth (2024-2031) | Gilead Sciences, Inc., Novartis, AG, Vericel Corporation - openPR
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Yahoo Finance
Simplify Asset Management Inc. Buys New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Option Exercise |
57.92 |
25,000 |
1,448,000 |
125,189 |
Parsey Merdad | Chief Medical Officer |
Nov 06 '24 |
Sale |
91.50 |
25,590 |
2,341,485 |
99,599 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):